Neurodegeneration and inflammation in MS
The eye teaches us about the storm
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In multiple sclerosis (MS), neurodegeneration contributes to axon loss and irreversible disability, but the degree to which neurodegeneration is a consequence of inflammatory mechanisms is unknown. Urgent need exists in all forms of MS, but especially in progressive MS, for therapies that preserve the integrity and function of CNS tissue in the face of a partially controlled chronic disease. It is likely that agents envisioned to fulfill that role (primary neuroprotective therapies) will act via a mechanism outside immune modulation. In analogous terms, the CNS could be likened to a home that we aim to protect from storm damage. Immune-modulating therapies are the equivalent of a weather machine that prevents the storm from ever brewing, and in that way provide indirect neuroprotection. Primary neuroprotection would be achieved by another mechanism, something akin to installing storm shutters or reinforcing the structure of a home to help it weather the years. The concern in MS is that ongoing neurodegeneration may occur even in the absence of detectable active inflammation, compelling a need for primary neuroprotective therapies that utilize novel mechanisms of action.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 47
- © 2012 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinningJohn N. Ratchford, Shiv Saidha, Elias S. Sotirchos et al.Neurology, December 24, 2012 -
Drugs and Devices
The application of optical coherence tomography in neurologic diseasesRamiro S. Maldonado, Pradeep Mettu, Mays El-Dairi et al.Neurology: Clinical Practice, September 17, 2015 -
Article
Optical coherence tomography is highly sensitive in detecting prior optic neuritisSarah Chaoying Xu, Randy H. Kardon, Jacqueline A. Leavitt et al.Neurology, January 23, 2019 -
Article
Functional–structural correlations in the afferent visual pathway in pediatric demyelinationE. Ann Yeh, Ruth Ann Marrie, Y. Arun Reginald et al.Neurology, October 31, 2014